IDEAYA Biosciences announces the latest development timeline for its Cdkn2a project
Show original
The company plans to determine its development candidate drug in the second half of 2026, followed by submitting a new drug clinical trial application in the first half of 2027. This progress marks the company's continued advancement in the field of tumor-targeted therapy.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
PoolX: Earn new token airdrops
Lock your assets and earn 10%+ APR
Lock now!
You may also like
Amazon expands access to Eli Lilly's weight loss drug Zepbound
格隆汇•2026/03/09 11:42
Trending news
MoreAccording to the latest documents submitted to the U.S. Securities and Exchange Commission (SEC), biopharmaceutical company Spruce Biosciences, Inc. has been authorized to offer and sell its common stock under the current sales agreement, with the total amount not exceeding the planned maximum limit.
Trevi Therapeutics (TRVI) has successfully completed the End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA).
Crypto prices
More
Bitcoin
BTC
$67,695.95
+0.31%
Ethereum
ETH
$1,993.48
+2.27%
Tether USDt
USDT
$0.9999
-0.01%
BNB
BNB
$626.87
+1.08%
XRP
XRP
$1.35
-0.70%
USDC
USDC
$1
+0.01%
Solana
SOL
$83.63
+0.99%
TRON
TRX
$0.2855
-0.35%
Dogecoin
DOGE
$0.09045
+1.36%
Cardano
ADA
$0.2549
+0.22%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now